Metabolism, mechanism of action and sensitivity profile of fluorocyclopentenylcytosine (RX-3117; TV-1360)

Fluorocyclopentenyl-cytosine with Broad Spectrum and Potent Antitumor Activity

(2012) Won Jun Choi et al.   JOURNAL OF MEDICINAL CHEMISTRY

Antiproliferative activity, mechanism of action and oral antitumor activity of CP-4126, a fatty acid derivative of gemcitabine, in in vitro and in vivo tumor models

(2010) Andries M. Bergman et al.   INVESTIGATIONAL NEW DRUGS

Trifluorothymidine Resistance Is Associated with Decreased Thymidine Kinase and Equilibrative Nucleoside Transporter Expression or Increased Secretory Phospholipase A2

(2010) Olaf H. Temmink et al.   MOLECULAR CANCER THERAPEUTICS

Induction of Resistance to the Lipophilic Cytarabine Prodrug Elacytarabine (CP-4055) in CEM Leukemic Cells

(2010) A. D. Adema et al.   NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS

Targeting DNA methylation for epigenetic therapy

(2010) Xiaojing Yang et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Decitabine in the treatment of myelodysplastic syndromes

(2009) Fabio PS Santos et al.   Expert Review of Anticancer Therapy

Decreased levels of UMP kinase as a mechanism of fluoropyrimidine resistance

(2009) R. Humeniuk et al.   MOLECULAR CANCER THERAPEUTICS

Gemcitabine chemoresistance in pancreatic cancer: Molecular mechanisms and potential solutions

(2009) Roland Andersson et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

Inhibition of cytidine deaminase by zebularine enhances the antineoplastic action of 5-aza-2′-deoxycytidine

(2008) Maryse Lemaire et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Contribution of the drug transporter ABCG2 (breast cancer resistance protein) to resistance against anticancer nucleosides

(2008) C. de Wolf et al.   MOLECULAR CANCER THERAPEUTICS

Will cyclopentenyl cytosine (CPEC) ever have a future in the clinic?

(2007) Chris van Bree et al.   LEUKEMIA RESEARCH